Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Featured trial
TriPRIL CAR T Cells in Multiple Myeloma

This research study involves the study drugs:.TriPRIL CAR T CellsFludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

  • 0 views
  • 24 Nov, 2025
  • 1 location
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

obinutuzumab
17p deletion
bendamustine
venetoclax
rituximab
  • 0 views
  • 19 Feb, 2024
  • 51 locations
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

b-cell lymphoma
leukapheresis
refractory follicular lymphoma
malt
systemic therapy
  • 0 views
  • 19 Feb, 2024
  • 36 locations
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.

oxygen saturation
fdg pet
blood bilirubin
chest x-ray
hypericum perforatum
  • 0 views
  • 19 Feb, 2024
  • 1 location
Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 19 Feb, 2024
  • 2 locations
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis

  • 0 views
  • 19 Feb, 2024
  • 1 location
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) …

solid neoplasm
serum bilirubin
monoclonal antibodies
kidney function test
immunohistochemistry
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a …

oral contraceptives
venetoclax
hydroxyurea
interleukin-3
treatment regimen
  • 0 views
  • 19 Feb, 2024
  • 1 location
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and …

myeloid leukemia
aptt
allogeneic hematopoietic stem cell transplant
immunohistochemistry
flow cytometry
  • 0 views
  • 19 Feb, 2024
  • 1 location